Discover cutting-edge studies on carcinogenesis, biomarkers, and targeted therapeutic approaches
Discover how THOR-707, a novel not-alpha IL-2 therapy, combined with pembrolizumab is revolutionizing cancer immunotherapy for advanced solid tumors.